KR20100113602A - 고체 형태의 약제 - Google Patents

고체 형태의 약제 Download PDF

Info

Publication number
KR20100113602A
KR20100113602A KR1020107019161A KR20107019161A KR20100113602A KR 20100113602 A KR20100113602 A KR 20100113602A KR 1020107019161 A KR1020107019161 A KR 1020107019161A KR 20107019161 A KR20107019161 A KR 20107019161A KR 20100113602 A KR20100113602 A KR 20100113602A
Authority
KR
South Korea
Prior art keywords
ethynyl
diol
androstan
crystalline
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107019161A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 케이. 화이트
드와이트 스틱니
에린 올슨
키이쓰 알. 로리머
브렌톤 에스. 울프
Original Assignee
하버 바이오사이언시즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하버 바이오사이언시즈 인코포레이티드 filed Critical 하버 바이오사이언시즈 인코포레이티드
Publication of KR20100113602A publication Critical patent/KR20100113602A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020107019161A 2008-02-05 2009-02-05 고체 형태의 약제 Ceased KR20100113602A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2647208P 2008-02-05 2008-02-05
US61/026,472 2008-02-05
US9369408P 2008-09-02 2008-09-02
US61/093,694 2008-09-02

Publications (1)

Publication Number Publication Date
KR20100113602A true KR20100113602A (ko) 2010-10-21

Family

ID=40952461

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107019161A Ceased KR20100113602A (ko) 2008-02-05 2009-02-05 고체 형태의 약제

Country Status (10)

Country Link
US (4) US8518922B2 (enExample)
EP (1) EP2249838A4 (enExample)
JP (1) JP2011511011A (enExample)
KR (1) KR20100113602A (enExample)
CN (2) CN101939009B (enExample)
AU (1) AU2009212314C1 (enExample)
CA (1) CA2712005C (enExample)
EA (1) EA018974B9 (enExample)
IL (1) IL207378A0 (enExample)
WO (1) WO2009100258A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102534C2 (xx) 2007-12-07 2013-07-25 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДА ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДІОКСОЛ-5-ІЛ)-ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ (ВАРІАНТИ)$ТВЕРДАЯ ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДИОКСОЛ-5-ИЛ)-ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ (ВАРИАНТЫ)
CA2728889C (en) * 2008-04-03 2016-06-14 Harbor Biosciences, Inc. Solid state forms of a pharmaceutical
EP2506855A4 (en) * 2009-11-30 2014-07-30 Harbor Biosciences Inc ANTICARCINOMA COMPOUNDS AND SCREENING METHODS
AU2011205230A1 (en) 2010-01-13 2012-08-02 Caris Life Sciences Switzerland Holdings Gmbh Detection of gastrointestinal disorders
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
WO2012083161A1 (en) * 2010-12-17 2012-06-21 Harbor Biosciences, Inc. Steroid tetrol solid state forms
CN104173353B (zh) * 2013-05-22 2018-08-21 中国医药工业研究总院 不含表面活性剂的固体制剂及其制备方法
BR112016010403A2 (pt) * 2013-11-12 2017-08-08 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
CN108883067B (zh) 2015-12-15 2021-03-09 康特斯生物制药公司 非晶奥那司酮组合物及其制备方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
IL269667B2 (en) * 2017-03-30 2024-09-01 Merck Patent GmbH Solid forms of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl) methanol, its preparation and pharmaceutical compositions containing them
RU2668526C1 (ru) * 2017-08-18 2018-10-01 Федеральное государственное бюджетное учреждение "Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения" Федеральной службы по надзору в сфере здравоохранения Способ идентификации и последующего количественного определения основных компонентов в инъекционных лекарственных средствах
AU2019389175B2 (en) 2018-11-30 2025-03-06 Caris Mpi, Inc. Next-generation molecular profiling
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
EP4069865A4 (en) 2019-12-02 2023-12-20 Caris MPI, Inc. PLATINUM RESPONSE PREDICTOR IN A PAN-CANCER APPROACH

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE681869C (de) * 1935-11-22 1939-10-03 Schering Ag Verfahren zur Darstellung von tertiaeren Alkoholen der Cyclopentanopolyhydrophenanthrenreihe
CH202847A (de) * 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
DE69325253T2 (de) * 1992-08-28 1999-12-02 Bone Care International Inc., Madison 1alpha,24(s)-dihydroxy vitamin d2, seine synthese und verwendung
US5567830A (en) * 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
AU708053B2 (en) 1996-03-29 1999-07-29 Duphar International Research B.V. Piperazine and piperidine compounds
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
EP1832598A3 (en) * 1999-09-30 2008-01-02 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatment of androgen receptor driven conditions
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SK288222B6 (sk) * 2000-12-14 2014-09-04 Ortho-Mcneil Pharmaceutical, Inc. Steroidné hormonálne prípravky a spôsoby ich prípravy
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US7540016B2 (en) * 2004-07-21 2009-05-26 Beachhead Solutions, Inc. System and method for lost data destruction of electronic data stored on a portable electronic device which communicates with servers that are inside of and outside of a firewall
US7964604B2 (en) * 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
TW200730505A (en) * 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
TWI305979B (en) * 2006-03-24 2009-02-01 Hon Hai Prec Ind Co Ltd Wireless transceiving system
PL2012773T3 (pl) * 2006-04-22 2012-12-31 Harbor Biosciences Inc Leki i zastosowania
DE102007063671A1 (de) * 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Also Published As

Publication number Publication date
EA018974B9 (ru) 2014-04-30
AU2009212314C1 (en) 2014-05-08
CN103467554A (zh) 2013-12-25
CA2712005A1 (en) 2009-08-13
US20130345455A1 (en) 2013-12-26
AU2009212314B2 (en) 2013-11-21
US20090291932A1 (en) 2009-11-26
CN101939009B (zh) 2013-07-17
EP2249838A1 (en) 2010-11-17
EA018974B1 (ru) 2013-12-30
US20130338125A1 (en) 2013-12-19
CN101939009A (zh) 2011-01-05
CA2712005C (en) 2014-04-15
AU2009212314A1 (en) 2009-08-13
IL207378A0 (en) 2010-12-30
JP2011511011A (ja) 2011-04-07
HK1147695A1 (en) 2011-08-19
WO2009100258A1 (en) 2009-08-13
EA201070713A1 (ru) 2011-08-30
EP2249838A4 (en) 2012-05-02
US8518922B2 (en) 2013-08-27
US20130345184A1 (en) 2013-12-26
US9314471B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
KR20100113602A (ko) 고체 형태의 약제
JP6946194B2 (ja) キナーゼを調節する化合物の固体形態
US10995112B2 (en) Crystalline solvate forms of a pharmaceutical
CN119744262A (zh) 哌啶基-甲基-嘌呤胺d-酒石酸盐、晶型，及其在治疗医学疾病和病况中的用途
US20240115585A1 (en) Methods of treating cancer
CN113292621B (zh) 一种黄体酮的药物晶型及其应用
HK1147695B (en) Pharmaceutical solid state forms
JP2021522341A (ja) イソキノリノンの多形及びアモルファス形態ならびにその使用方法
HK1157679A (zh) 藥學試劑的固體形式

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100827

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120903

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131210

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140627

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131210

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I